

OPPORTUNITY TO PARTICIPATE IN A CLINICAL TRIAL

Mechanistic trial of dupilumab in adults with house dust mite-associated asthma using an aeroallergen challenge chamber

SHORT TITLE - Dupilumab effects against aeroallergen challenge

DO YOU HAVE MILD TO MODERATE ASTHMA AND ALLERGY SYMPTOMS YEAR-ROUND?

Biogenics Research Chamber and The University of Texas Health Science Center San Antonio (UTHSA) are conducting a clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The goal of this trial is to learn if the study medication dupilumab (Dupixent®) given by injection will make a difference in the nose of people who have asthma and are allergic to house dust mites.

Your participation in the trial will be about 8 months but could last up to 10 months depending on when you begin.

TO QUALIFY FOR THIS STUDY, YOU MUST:

- 1. Be allergic to House Dust Mites and have a history of allergy symptoms
- 2. Have mild to moderate asthma with or without medication use.
- 3. Be 18 to 65 years old.
- 4. Not be taking any allergy shots.
- 5. Not be taking steroid tablets by mouth or steroids by injection
- 6. Not be a current smoker
- 7. Be able to stop taking asthma medication for 4 days and allergy medications for 7 days before some visits. You can always use your rescue inhaler (like albuterol) as prescribed.

WHAT'S INVOLVED?

- 20 study visits to Biogenics Research Chamber. This includes a screening visit to see if you qualify for the study
- If you qualify, you will be exposed to house dust mite allergen in a room called an Aeroallergen challenge chamber that delivers controlled levels of allergens at 6 different visits

Protocol: U01-UTHSA-01

BIEGENICS RESEARCH CHAMBER

- You will be in the room for 5 hours. While being exposed to the house dust mite, you may have increased nose and asthma symptoms.
- If you are selected to continue in the study after the first exposure to house dust mite, then you will be assigned by chance to receive either the study drug dupilumab or placebo for dupilumab injections. The placebo does not have any medicine in it.
- Injections will be given every 2 weeks for 9 of the visits.
- Blood will be collected at 13 of the visits. Blood is collected before and after each house dust mite exposure.
- Except for the first visit, samples are collected from your nose at each study visit.

You will be compensated for time and travel for each visit completed during the study.

If you are interested in receiving more information, please call or text:

Recruitment Nurse: Nicky Skelton, R.N.

Phone: (210) 614-2564

Biogenics Research Chamber 8255 Fredericksburg Road San Antonio, TX 78229

Principal Investigator: Robert L. Jacobs, MD